Article
Dr. Jack Cush talks of birthdays, Quizzes and journal articles this week on the podcast.
All News
Article
UCB has released the Week 16 results from BE BOLD trial that will be presented at EULAR 2026 in London on Saturday, June 6.
Article
Plasmacytoid dendritic cells (pDCs) have been strongly implicated in the pathogenesis of lupus, as their primary product, type I interferon, drive systemic lupus erythematosus and cutaneous lupus erythematosus. A recent comprehensive review synthesizes the available data on pDCs, and, importantly, what we still don't know.
Article
Rheumatology has published a cohort study showing that earlyGI symptoms and overall symptom burden predict both GI progression and mortality in Systemic Sclerosis (SSc).
Dr. John Cush
Tweet
FDA has approved benralizumab (Fasenra) for the treatment of adult and pediatric patients w/ hypereosinophilic syndrome (HES); based on the NATRON Phase III trial https://t.co/7se6qLsQoP https://t.co/64wC94hTTq
Dr. John Cush
Tweet
Another IL-17A inhibitor (Vunakizumab) for active Ankylosing Spondylitis
Vunakizumab, a novel anti–interleukin (IL) 17A monoclonal antibody, was studied in patients with active radiographic axial spondyloarthritis [r-axSpA] and found to be effective and tolerable. https://t.co/4WMLbcPLOs
Dr. John Cush
Tweet
Fatigue in SLE
An NIH lupus cohort study looked at fatigue in SLE and found associations with organ damage, obesity, but does not correlate with disease activity in systemic lupus erythematosus (SLE) patients.
https://t.co/63JVDUwu88 https://t.co/3dPOThMbMD
Dr. John Cush
Tweet
Can’t attend #EULAR2026?
You won’t miss a thing.
RheumNow delivers:
📬 Daily summaries
🎥 Interviews
📊 Key data highlights
Follow https://t.co/V10S4oVFsv June 3–6. https://t.co/7Xdj94eFu4
Dr. John Cush
Tweet
Early GI Involvement Predictive of Scleroderma Outcomes
Rheumatology has published a cohort study showing that earlyGI symptoms and overall symptom burden predict both GI progression and mortality in Systemic Sclerosis (SSc).
https://t.co/ftz6TeZv5Z https://t.co/Nw3wQ06VTq
Dr. John Cush
Tweet
Immune-Mediated Inflammatory Diseases Following Uveitis
A Korean insurance claims data study showed children and adolescents diagnosed with uveitis have a 7-fold increased risk of developing an immune-mediated inflammatory disorder (IMID).
https://t.co/NJI4369ygL https://t.co/6mHK8hYMeG
Dr. John Cush
Tweet
HCQ: 5 mg/kg/day Is Only the Starting Point
HCQ is one of the most important drugs in rheumatology, especially for SLE. It reduces flares, organ damage, cardiovascular events, and pregnancy complications, and it improves survival. Yet many clinicians still prescribe HCQ as if https://t.co/Fwr92tuZf2
Dr. John Cush
Tweet
Does Exercise and Lifestyle Modification Improve RA?
Do exercise or lifestyle modifications reduce the risk of getting RA or change those with early RA? A current review and meta-analysis found no studies addressing the benefit in pre-clinical RA, but found evidence that https://t.co/Bvp3Ery5Fg
Dr. John Cush
Tweet
Does RTX work in CNS lupus? Japanese experience in 17 refractory NP-SLE pts Rx w/ RTX - 16/17 had significant improve. & 1 partial improvement -- none had NP-SLE relapse. Two died during COVID> https://t.co/GpCgpSxn37 https://t.co/PMz05MHBhj
Dr. John Cush
Tweet
Press release of early study of IMVT-1402 (human mAb targeting FcRn) Open-label Rx in 170 active, refractory RA showed ACR 20/50/70 of 73%/54%/36% at wk 16. Next, Responders will do a blinded withdrawl - blinded results to follow. https://t.co/Mzmb3PPvMF https://t.co/oZ99l9VJQU
Dr. John Cush
Tweet
RheumNow’s global faculty reporters help translate the data into clinical practice.
Featuring:
✨ Dr. Janet Pope (@Janetbirdope)
✨ Dr. Yuz Yusof (@Yuz6Yusof)
✨ Dr. Jiha Lee (@JihaRheum)
✨ Dr. Mrinalini Dey (@DrMiniDey)
✨ Dr. Aurelie Najm (@AurelieRheumo)
✨ Dr. Bella https://t.co/0Pm0uUwRNf
Dr. John Cush
Tweet
True or False: In a registry of SLE patients, RNP-positive patients showed lower disease activity and less prednisone use. If you think you know the answer, prove it in this week's RheumIQ quiz at https://t.co/DTabBEfjj9
Dr. John Cush
Tweet
Kissei Pharmaceuticals announced 20 deaths related to receiving avacopan (Tavneos), a vasculitis drug sold by the firm in Japan. Drug was released in June 2022, since its been given to ~8,500 pts. Avacopan safety is being reviewed by FDA with Amgen. https://t.co/ri0nROCL5U https://t.co/jbksrWMFwI
Dr. John Cush
Tweet
FDA has approved a dosing update for burosumab-twza (Crysvita, Kyowa Kirin) to allow for increased dose and frequency when needed in adults with X-linked hypophosphatemia (XLH). https://t.co/EPyp6tDsaf https://t.co/1HEaQRk9BR
Dr. John Cush
Tweet
Goofy study of the month! (pub in JAMA!) RCT 170 adults w/ chronic LBP + MRI disc herniation found that amoxicillin-clavulanate, 500 mg/125 mg bid x 3 mos did not improve pain at 3 or 12 mos (vs PBO). Whatha... https://t.co/njrw6itAP8 https://t.co/CW2ssNPxf1
Dr. John Cush
Tweet
Prospective study of 40 newly Dx, Tx-naïve RA pts starting MTX; Of serum cytokines tested, high baseline IL-6 & IL-17 was assoc w/ nonresponse to MTX. Yet, still not good response biomarkers. TNF-α & GM-CSF did not assoc w/ MTX outcomes https://t.co/YIQKop9LMH https://t.co/XxwcRsKwoM
